Background: Spinal Muscular Atrophy type 1 (SMA1) is a rare genetic neuromuscular
hospitalization rate over the follow-up period. This contrasts with the natural history of progressive respiratory failure and reduced survival. The reduced healthcare utilization could potentially alleviate patient and caregiver burden, suggesting an overall improved quality of life following gene replacement therapy. phenotype is the most severe and accounts for 60% of SMA patients; it is the most common genetic cause of death in infants. 2 The onset of symptoms for SMA1 occurs shortly after birth and prior to six months of age with a clinical hallmark of the inability to achieve independent sitting. 3, 4 Infants with SMA1 rapidly lose motor function and ultimately succumb to respiratory complications often within the first year of life.
Longitudinal observational studies of SMA1 infants with two SMN2 copies who were offered standard of care 5 showed a median age of death or permanent ventilation (≥16 h/day for at least 14 consecutive days) that ranged from 8 months 6 to 10.5 months. 3 Based on the published consensus statements for the standard of care of SMA, 7, 8 many centers have adopted the use of non-invasive ventilation (NIV) and aggressive chest clearance to help manage the respiratory complications of SMA1. These standards also include guidance to provide enteral nutritional support early due to the loss of bulbar function in the natural history of the disease.
Most SMA1 patients experience the complications of respiratory failure and dysphagia that necessitate interventions (eg, nasogastric tube or gastrostomy tube placement and initiation of NIV or intubation leading to tracheostomy, respectively) to prolong patient survival. 3 Natural history studies show that in patients older than 12 months, 100% required nutritional or combined nutritional and ventilation support, 3 and 61% of SMA1 patients required ≥1 intubation within the first year of life. 9 compared to historical cohorts. 3, 6 In this report, we aim to describe and expand upon the health outcomes of SMA1 patients treated with AVXS-101, including pulmonary support, swallow function, nutritional outcomes, hospitalization rate, and motor function.
| MATERIALS AND METHODS

| Study participants
As previously reported, 18 12 patients (Cohort 2) with a genetically confirmed diagnosis of SMA1 with homozygous SMN1 exon 7 deletions and two copies of SMN2 were enrolled in an open-label study With safety as a primary objective, time to death or permanent ventilation, defined as either ≥16 h/day for at least 14 consecutive days without an acute reversible illness or perioperative use, or tracheostomy placement, was a secondary objective and primary efficacy endpoint. 18 The study was approved by the Institutional Review Board of Nationwide Children's Hospital (no. IRB00000568), and written informed consent was obtained from parents or legal guardians.
| Follow-up
Follow-up was conducted on days 7, 14, 21, and 30 followed by monthly visits through 12 months post-dosing, and then every three months through two years post-dosing. The last study visit was conducted in December 2017. Outcomes described in this report include data from the full 24-month post-treatment follow-up period, including data previously published.
| Outcomes
The outcomes of interest included (1) Major motor milestones captured by video recording during visits were verified by an independent reviewer.
| Statistical analysis
Because statistical analysis was limited by the small sample size which is typical of rare diseases, descriptive statistics, such as frequencies and percentages, and means with ranges and/or standard deviations, were reported for the outcomes of interest.
3 | RESULTS
| Assessment of pulmonary support
At baseline (mean age 3.4 months, range [0.9-7.9]), 10 of 12 (83%) patients did not require NIV, and no patient required a tracheostomy at any time throughout the 2-year study period (Table 1) . 18 As of their final study visit, 7 of the 10 patients who did not require ventilatory support before dosing completed the study without any ventilatory support. All three patients who did not require NIV at baseline but required it postdosing had an early onset of symptoms in the first month of life and a rapid disease progression characterized by diffuse muscle weakness, respiratory insufficiency, and inability to swallow.
The NIV was required in the context of viral illnesses and was maintained thereafter. All five infants who required NIV at the final study visit remained stable post-dosing, as none reached the pulmonary endpoint.
| Evaluation of nutritional support, swallow function, and speech
At baseline, 7 of 12 (58%) patients were able to feed orally and did not require supplemental nutritional support, defined as enteral feeding ( Figure 1) . 18 At the end of the follow-up period, 6 of those 7 (86%) patients continued to eat exclusively by mouth.
Video-fluoroscopic swallow studies showed that the number of patients who achieved safe swallow function using thin liquids increased from 4 (33%) patients pre-treatment to 10 (83%) patients at the end of the follow-up period (Figure 1 ). The number of patients able to safely swallow to allow for at least partial oral feeding increased from 7 (58%) patients at baseline to 11 (92%) patients at the end of the follow-up period (Figure 1 ).
Because bulbar-innervated muscle function deterioration can negatively influence the ability of SMA1 patients to speak, 22 we also analyzed speech following AVXS-101 treatment. As shown in Table 2, 11 of 12 (92%) patients were able to speak by the end of the study. patients who were not using NIV at baseline, but required this support during their hospitalization for acute illness. All three patients returned to requiring no support at discharge.
The mean proportion of study time hospitalized was 4.4%
(range = 0, 18.3%) for patients treated with AVXS-101; 10 (83%) patients were hospitalized <10% of the time, and none were hospitalized ≥20% of the time. In addition, the mean unadjusted annualized rate of hospitalizations (total hospitalizations/total number of subject-years followed) was 2.1 (range = 0, 7.6), and the mean LOS per hospitalization was 6.7 days (range = 3, 12.1)
for the 10 patients who were hospitalized after treatment with AVXS-101.
| Motor milestone assessments
Following AVXS-101 treatment, 11 of the 12 (92%) infants achieved full head control and were able to sit unassisted. All 11 sat for ≥5 s, 10 (83%) sat unassisted for ≥10 s, and 9 (75%) could sit unassisted for ≥30 s during the 2-year follow-up period (Table 2) . During the study, 9 (75%) patients were able to roll and 2 (17%) were able to crawl, pull to stand, and stand and walk independently. Continued long-term follow-up of the patients beyond the 2-year period revealed ongoing motor milestone achievements; two additional children developed the ability to sit unassisted for ≥30 s (11 [92%] total), and two additional children were able to stand with support (4 [33%] total; BiPAP use is parent reported (for the most part, parents report hours used per night and hours used for naps).
a BiPAP was needed in these children because of hospitalizations for respiratory infections.
FIGURE 1 Stabilization or improvement in swallow function in the AVXS-101 proposed therapeutic dose group (n = 12). Swallow function was determined by a video-fluoroscopic swallowing test at baseline and every 6 months during the follow-up period. *In one patient, a gastrostomy placement was performed to enhance nutrition to improve wound healing and recovery from a difficult postoperative course after scoliosis surgery replacement therapy was able to preserve respiratory function in a cohort of symptomatic SMA1 infants with two copies of the SMN2 gene; 70% of patients who did not require assisted ventilation prior to treatment were able to continue without such support for >2 years following treatment. 3 Remarkably, 92% of patients experienced stabilization or improvement in swallowing function and nutritional support. Compared to previous natural history studies of SMA1 patients, the present study had a lower mean number of annual inpatient admissions (2.1 versus 4.2 10 to 7.6 11 hospitalizations/year, respectively) and mean LOS (6.7 versus 13 days, 12 respectively).
Participants also experienced only 1.4 respiratory hospitalizations per year, and no patients hospitalized for respiratory illnesses required a tracheostomy or prolonged invasive ventilation greater than 8 days.
Regarding indicators of motor function, 92% of patients achieved full head control and the ability to sit independently for ≥5 s and were able to speak. As previously reported, 18 the only adverse event believed to be related to the viral vector gene therapy is a transient asymptomatic elevation of liver enzymes that was managed with a brief course of steroids. Taken together, AVXS-101 appears to transform the disease course with regard to respiratory and nutritional complications, hospitalizations, and motor functioning and raises the possibility of subsequent functional independence for SMA1 patients.
Along with reductions in the average number of hospitalizations and LOS compared to natural history, patients treated with AVXS-101 also spent less time hospitalized compared to the control group in the ENDEAR study (mean proportion of study time hospitalized, 4.4% versus 18.5%, respectively). 23 This randomized, sham-controlled, Phase 3 trial evaluating the clinical efficacy and safety of nusinersen had closely comparable study criteria and populations compared to the current study (ie, genetically confirmed SMA1 patients with homozygous SMN1 exon 7 deletions and two SMN2 copies). In addition, 83%
(10/12) of the patients treated with AVXS-101 were hospitalized <10%, and none were hospitalized ≥20% of the 2-year follow-up period in contrast to the that observed in the control group of SMA1 patients who were enrolled as part of the ENDEAR study (41% were hospitalized <10% of the time and 37% were hospitalized ≥20% of the time; Figure 2 ). 23 Qualitative studies have shown that SMA patients and their caregivers view small changes in motor function and maintenance of function as highly impacting patients' QoL. 16 In the context of treatment development, SMA patients reported that the functional activity they would most like to be preserved or improved was "respiratory functions (improvement or stabilization, including coughing and swallowing)." 24 Given that management of symptoms can improve 25 Standing assisted 100  92  75  92  92  92  92  33 Single checks, 24-month follow-up; *Long-term follow-up. 
